[
  {
    "ts": null,
    "headline": "Amgen Set to Report Q4 Earnings: What Investors Should Know",
    "summary": "AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.",
    "url": "https://finnhub.io/api/news?id=5fb362265004804365297da010696e14caad47475b515f388ba8e129ad6026c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769617440,
      "headline": "Amgen Set to Report Q4 Earnings: What Investors Should Know",
      "id": 138285164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.",
      "url": "https://finnhub.io/api/news?id=5fb362265004804365297da010696e14caad47475b515f388ba8e129ad6026c5"
    }
  },
  {
    "ts": null,
    "headline": "NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold",
    "summary": "Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.",
    "url": "https://finnhub.io/api/news?id=dd4d44832b5c104be0f2b6ff83b2c0820775c3f5ec5d85715c04eac2aa71a491",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611500,
      "headline": "NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold",
      "id": 138285339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.",
      "url": "https://finnhub.io/api/news?id=dd4d44832b5c104be0f2b6ff83b2c0820775c3f5ec5d85715c04eac2aa71a491"
    }
  },
  {
    "ts": null,
    "headline": "Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?",
    "summary": "REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.",
    "url": "https://finnhub.io/api/news?id=946847f5d22043c16a9148ec0bb8dfac07b539abc6c64b773e04e9869df070f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609460,
      "headline": "Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?",
      "id": 138281686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.",
      "url": "https://finnhub.io/api/news?id=946847f5d22043c16a9148ec0bb8dfac07b539abc6c64b773e04e9869df070f3"
    }
  }
]